Featured

ChemoLock

The first needlefree CSTD to receive FDA 510(k) clearance for both pharmacy compounding (ONB) and patient administration (FPA) applications.

Oncology Products

Clinical Evidence

Generic File Icon Image
Microbial Ingress Study for ChemoLock™ Devices
Report of a study commissioned by ICU and conducted by AAIPharma Services
Generic File Icon Image
Evaluation of ICU Medical’s ChemoLock ™ System Using Methotrexate (MTX) as a Marker
Conducted at RJ Lee Group, Inc., Greene County, PA
Generic File Icon Image
Hazardous Drug Compatibility with the ChemoClave™ System
Generic File Icon Image
Evaluation of Surface Contamination with Cyclophosphamide Following Simulated Hazardous Drug Preparation Activities Using Two Closed-System Products
Zock M, Soefje S, Rickabaugh K, Journal of Oncology Pharmacy Practice, Aug 10, 2010
Generic File Icon Image
Cost Determination Study of Closed System Transfer Devices (CSTD)
Barnachea L, Lee T, Gitler J, Saria M. Presented at the California Society of Health System Pharmacists (CSHP), November 4, 2011
Generic File Icon Image
Economic and Environmental Impact of Commercially Available Closed System Transfer Devices (CSTDs)
How the ICU Medical ChemoClave™ can provide nearly $482K in annual cost savings while generating more than 3,200 fewer pounds of biohazardous waste per year
Generic File Icon Image
Creating a Culture of Closure: Implementation of the ICU Medical Chemotherapy Closed System for Antineoplastic Agent Administration
Moore A, Wiley K, Maloney K, Holmes M, Hospital of the University of Pennsylvania. Presented at the Oncology Nursing Society Meeting, May 2012
Generic File Icon Image
Performance Evaluation of the PhaSeal® Luer Lock Injector (N35) and Connector™ Luer Lock (C45 & C40) in a Lab Study
Moore A, Wiley K, Maloney K, Holmes M, Hospital of the University of Pennsylvania. Presented at the Oncology Nursing Society Meeting, May 2012
Generic File Icon Image
Dirty Little Secrets: Hazardous Drug Contamination at the Chairside
Hodges L., Caskey C. Section on Hematology and Oncology/Environmental Health and Safety Department, Wake Forest University School of Medicine
Generic File Icon Image
Spiros: Mechanically and Microbiologically Closed Male Luer
Hodges L., Caskey C. Section on Hematology and Oncology/Environmental Health and Safety Department, Wake Forest University School of Medicine
Generic File Icon Image
Improving Chemotherapy Safety via Use of ChemoClave® System (Spiros®), Priming Technique, DoseEdge™, and Volutrols
Michelle Abitz, RN; Caitlyn Burdock, RN, BSN; Micha Koentz, BS, PharmD; Rhiannon McDonnell, RN, BSN; Heidi Trinkman, BS, PharmD
Generic File Icon Image
Reducing Hazardous Drug Exposure: Are All Closed Systems Created Equal?
Karen Sachse, MSN, RN, CPON, CNS-BC, Margaret Perry, BSN, RN, CPHON, CPN, and Radha Rohatgi, Pharm D, BCOP, Hematology and Oncology, Children’s National Medical Center, Washington, DC